丹芪偏瘫胶囊对神经系统的作用.pdfVIP

Neuropharmacology 58 (2010) 987e1001 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevi /locate/neuropharm Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo C. Heurteaux a, *, C. Gandin a, M. Borsotto a, C. Widmann a, F. Brau a, M. Lhuillier b, B. Onteniente b, M. Lazdunski a, * a Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifi que (CNRS), Université de Nice Sophia Antipolis, 660 Route des Lucioles, 06560 Valbonne, France b INSERM UMR 861, Université dEvry, 5 rue Henri Desbrueres, 91030 Evry cedex, France a r t i c l e i n f o a b s t r a c t Article history: Although stroke remains a leading cause of death and adult disability, numerous recent failures in clinical Received 4 September 2009 stroke trials have led to some pessimism in the field. Interestingly, NeuroAid (MLC601), a traditional Received in revised form medicine, particularly used in China, South East Asia and Middle East has been reported to have beneficial 1 December 2009 effects in patients, particularly in post-stroke complications. Here, we demonstrate in a rodent model of Accepted 4 January 2010 focal ischemia that NeuroAid II (MLC901) pre- and post-treatments up to 3 h after stroke improve survival, protect the brain from the ischemic injury and drastically decrease functional deficits.